RFG Advisory LLC Makes New $73,000 Investment in ProQR Therapeutics (NASDAQ:PRQR)

RFG Advisory LLC purchased a new position in shares of ProQR Therapeutics (NASDAQ:PRQR) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 32,000 shares of the biopharmaceutical company’s stock, valued at approximately $73,000.

ProQR Therapeutics Stock Performance

Shares of PRQR opened at $1.65 on Thursday. The company has a market capitalization of $134.24 million, a P/E ratio of -4.46 and a beta of 0.35. ProQR Therapeutics has a one year low of $1.11 and a one year high of $3.29. The stock has a 50-day moving average price of $1.89 and a 200 day moving average price of $2.04.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. ProQR Therapeutics had a negative return on equity of 61.58% and a negative net margin of 260.75%. The firm had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.31 million. As a group, equities research analysts forecast that ProQR Therapeutics will post -0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PRQR has been the subject of several research analyst reports. Chardan Capital restated a “buy” rating and set a $2.50 price target on shares of ProQR Therapeutics in a research note on Friday, May 10th. StockNews.com lowered ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, June 21st. Citigroup increased their target price on ProQR Therapeutics from $1.80 to $2.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of ProQR Therapeutics in a research note on Friday, May 10th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $3.38.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).